Dec 29, 2025 • Yahoo Finance
BULLISH
ImmunityBio Founder Dr. Patrick Soon-Shiong Recognized as One of "100 Most Influential People in Oncology in 2025"
Dr. Patrick Soon-Shiong, Founder, Executive Chairman, and Global Chief Scientific and Medical Officer of ImmunityBio, has been named one of "The 100 Most Influential People in Oncology in 2025" by OncoDaily. This recognition highlights his extensive scientific accomplishments and leadership in advancing cancer care, reflecting his lifelong commitment to science, medicine, and patient care. ImmunityBio, a commercial-stage immunotherapy company, aims to develop next-generation therapies to combat cancers and infectious diseases.
Dec 29, 2025 • TradingView — Track All Markets
SOMEWHAT-BULLISH
ImmunityBio Signs Amendment to Open Market Sale Agreement With Jefferies
ImmunityBio (IBRX) has signed Amendment No. 1 to its Open Market Sale Agreement with Jefferies, significantly expanding its at-the-market equity offering program. This amendment allows for the issuance of up to an additional $459,972,480 in common stock and updates administrative procedures, providing the company with greater financing flexibility. The agreement aims to increase ATM capacity and streamline settlement processes.
Dec 25, 2025 • Simply Wall Street
NEUTRAL
ImmunityBio (IBRX) Valuation Check After New ANKTIVA Bladder Cancer Data in The Journal of Urology
ImmunityBio's ANKTIVA, in combination with BCG, has shown promising long-term results in bladder cancer, with new data published in The Journal of Urology. Despite recent stock price declines, Simply Wall St's discounted cash flow model suggests the stock may be undervalued, trading below its estimated fair value. However, the company's current price-to-sales ratio appears high compared to industry peers, indicating that potential risks to ANKTIVA's commercialization could impact its valuation.
Dec 25, 2025 • Simply Wall Street
SOMEWHAT-BULLISH
ImmunityBio (IBRX) Valuation Check After New ANKTIVA Bladder Cancer Data in The Journal of Urology
ImmunityBio (IBRX) has received new data in The Journal of Urology for its ANKTIVA bladder cancer treatment, showing sustained efficacy at 12 and 36 months when combined with BCG. Despite recent share price declines, the company's valuation presents a mixed picture. While the price-to-sales ratio appears high compared to peers, Simply Wall St's discounted cash flow model suggests the stock may be undervalued when considering future growth potential.
Dec 24, 2025 • StocksToTrade
BEARISH
Latest IBRX Insights: Stock Movement and Corporate Developments
ImmunityBio Inc. (IBRX) stocks have recently declined by 7.71% due to market sentiment concerns, highlighted by a drop from $2.25 to $2.095. While the company achieved positive gross profit margins and increased operating revenue, significant expenses and a substantial long-term debt continue to impact its liquidity and net income. Strategic partnerships and capital allocation will be crucial for IBRX to stabilize and potentially grow amidst a volatile market.
Dec 23, 2025 • MarketBeat
SOMEWHAT-BEARISH
ImmunityBio (NASDAQ:IBRX) Shares Down 5.1% - Here's What Happened
ImmunityBio (NASDAQ:IBRX) shares dropped 5.1% during mid-day trading on Tuesday, closing at $2.155 on unusually light volume. Analyst sentiment remains mixed-to-positive with an average "Moderate Buy" rating and a consensus price target of $10.40. The company, which specializes in immunotherapies for cancer and infectious diseases, recently beat Q3 earnings expectations.